Myeloproliferative Disorders
"Myeloproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Descriptor ID |
D009196
|
| MeSH Number(s) |
C15.378.190.636
|
| Concept/Terms |
Myeloproliferative Disorders- Myeloproliferative Disorders
- Disorder, Myeloproliferative
- Disorders, Myeloproliferative
- Myeloproliferative Disorder
|
Below are MeSH descriptors whose meaning is more general than "Myeloproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Myeloproliferative Disorders".
This graph shows the total number of publications written about "Myeloproliferative Disorders" by people in this website by year, and whether "Myeloproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 6 | 1 | 7 |
| 2004 | 3 | 0 | 3 |
| 2005 | 5 | 1 | 6 |
| 2006 | 10 | 2 | 12 |
| 2007 | 14 | 0 | 14 |
| 2008 | 8 | 2 | 10 |
| 2009 | 9 | 1 | 10 |
| 2010 | 17 | 1 | 18 |
| 2011 | 10 | 1 | 11 |
| 2012 | 11 | 2 | 13 |
| 2013 | 8 | 5 | 13 |
| 2014 | 17 | 2 | 19 |
| 2015 | 16 | 3 | 19 |
| 2016 | 13 | 2 | 15 |
| 2017 | 14 | 1 | 15 |
| 2018 | 17 | 0 | 17 |
| 2019 | 18 | 0 | 18 |
| 2020 | 11 | 3 | 14 |
| 2021 | 21 | 1 | 22 |
| 2022 | 25 | 0 | 25 |
| 2023 | 24 | 0 | 24 |
| 2024 | 7 | 9 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloproliferative Disorders" by people in Profiles.
-
Integrated Clinical Genotype-Phenotype Characteristics of STAT3-Mutated Myeloid Neoplasms. Clin Cancer Res. 2024 Oct 15; 30(20):4681-4689.
-
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. Am J Clin Pathol. 2024 Sep 03; 162(3):233-242.
-
Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms. J Clin Oncol. 2024 Nov; 42(31):3739-3750.
-
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024 Jul; 25(10):1391-1404.
-
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer. 2024 Oct 15; 130(20):3452-3462.
-
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
-
TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma. 2024 Oct; 65(10):1511-1515.
-
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. Br J Haematol. 2024 Jul; 205(1):48-60.
-
STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica. 2024 06 01; 109(6):1825-1835.
-
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.